-DOCSTART- -X- O
BACKGROUNDS -X- _ O
: -X- _ O
Urokinase -X- _ B-Comparison
( -X- _ I-Comparison
UK -X- _ I-Comparison
) -X- _ I-Comparison
2 -X- _ I-Comparison
200 -X- _ I-Comparison
U -X- _ I-Comparison
/ -X- _ I-Comparison
kgÂ·h -X- _ I-Comparison
for -X- _ I-Comparison
12 -X- _ I-Comparison
hours -X- _ I-Comparison
infusion -X- _ I-Comparison
( -X- _ I-Comparison
UK-12 -X- _ I-Comparison
h -X- _ I-Comparison
) -X- _ I-Comparison
is -X- _ O
an -X- _ O
ACCP -X- _ O
recommended -X- _ O
regimen -X- _ O
in -X- _ O
treating -X- _ O
acute -X- _ B-Patient
pulmonary -X- _ I-Patient
embolism -X- _ I-Patient
( -X- _ I-Patient
PE -X- _ I-Patient
) -X- _ I-Patient
. -X- _ O
It -X- _ O
is -X- _ O
unclear -X- _ O
whether -X- _ O
this -X- _ O
dose -X- _ O
and -X- _ O
time -X- _ O
can -X- _ O
be -X- _ O
reduced -X- _ O
further. -X- _ O
We -X- _ O
compared -X- _ O
the -X- _ O
efficacy -X- _ B-Outcome
and -X- _ I-Outcome
safety -X- _ I-Outcome
of -X- _ O
20 -X- _ B-Intervention
, -X- _ I-Intervention
000 -X- _ I-Intervention
U -X- _ I-Intervention
/ -X- _ I-Intervention
kg -X- _ I-Intervention
for -X- _ I-Intervention
2 -X- _ I-Intervention
hours -X- _ I-Intervention
( -X- _ I-Intervention
UK-2 -X- _ I-Intervention
h -X- _ I-Intervention
) -X- _ I-Intervention
with -X- _ O
the -X- _ O
UK-12 -X- _ B-Comparison
h -X- _ I-Comparison
regime -X- _ I-Comparison
in -X- _ O
selected -X- _ B-Patient
PE -X- _ I-Patient
patients. -X- _ I-Patient
METHODS -X- _ O
: -X- _ O
A -X- _ O
randomized -X- _ O
trial -X- _ O
involving -X- _ O
129 -X- _ O
patients -X- _ O
was -X- _ O
conducted. -X- _ O
Patients -X- _ B-Patient
with -X- _ I-Patient
acute -X- _ I-Patient
PE -X- _ I-Patient
were -X- _ O
randomly -X- _ O
assigned -X- _ O
to -X- _ O
receive -X- _ O
either -X- _ O
UK-12 -X- _ B-Comparison
h -X- _ I-Comparison
( -X- _ I-Comparison
n -X- _ I-Comparison
= -X- _ I-Comparison
70 -X- _ I-Comparison
) -X- _ I-Comparison
, -X- _ O
or -X- _ O
UK-2 -X- _ B-Intervention
h -X- _ I-Intervention
( -X- _ I-Intervention
n -X- _ I-Intervention
= -X- _ I-Intervention
59 -X- _ I-Intervention
) -X- _ I-Intervention
. -X- _ O
The -X- _ O
efficacy -X- _ O
was -X- _ O
determined -X- _ O
by -X- _ O
the -X- _ O
improvement -X- _ O
of -X- _ O
right -X- _ O
heart -X- _ O
dysfunction -X- _ O
and -X- _ O
perfusion -X- _ O
defect -X- _ O
at -X- _ O
24 -X- _ O
h -X- _ O
and -X- _ O
14 -X- _ O
d -X- _ O
post -X- _ O
UK -X- _ B-Intervention
treatment. -X- _ I-Intervention
The -X- _ O
bleeding -X- _ O
incidence -X- _ O
, -X- _ O
death -X- _ O
rate -X- _ O
and -X- _ O
PE -X- _ O
recurrence -X- _ O
were -X- _ O
also -X- _ O
evaluated. -X- _ O
RESULTS -X- _ O
: -X- _ O
Similarly -X- _ B-Outcome
significant -X- _ I-Outcome
improvements -X- _ I-Outcome
in -X- _ I-Outcome
right -X- _ I-Outcome
heart -X- _ I-Outcome
dysfunction -X- _ I-Outcome
and -X- _ I-Outcome
lung -X- _ I-Outcome
perfusion -X- _ I-Outcome
defects -X- _ I-Outcome
were -X- _ I-Outcome
observed -X- _ I-Outcome
in -X- _ I-Outcome
both -X- _ I-Outcome
groups. -X- _ I-Outcome
Overall -X- _ I-Outcome
bleeding -X- _ I-Outcome
incidents -X- _ I-Outcome
were -X- _ I-Outcome
low -X- _ I-Outcome
in -X- _ I-Outcome
both -X- _ I-Outcome
groups. -X- _ I-Outcome
Major -X- _ I-Outcome
bleeding -X- _ I-Outcome
directly -X- _ I-Outcome
associated -X- _ I-Outcome
with -X- _ I-Outcome
UK -X- _ I-Outcome
infusion -X- _ I-Outcome
occurred -X- _ I-Outcome
in -X- _ I-Outcome
one -X- _ I-Outcome
patient -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
UK-2 -X- _ I-Outcome
h -X- _ I-Outcome
group -X- _ I-Outcome
and -X- _ I-Outcome
one -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
UK-12 -X- _ I-Outcome
h -X- _ I-Outcome
group. -X- _ I-Outcome
Mortality -X- _ I-Outcome
rates -X- _ I-Outcome
were -X- _ I-Outcome
low -X- _ I-Outcome
, -X- _ I-Outcome
with -X- _ I-Outcome
one -X- _ I-Outcome
reported -X- _ I-Outcome
fatal -X- _ I-Outcome
recurrent -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
UK-12 -X- _ I-Outcome
h -X- _ I-Outcome
group -X- _ I-Outcome
and -X- _ I-Outcome
none -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
UK-2 -X- _ I-Outcome
h -X- _ I-Outcome
group. -X- _ I-Outcome
When -X- _ I-Outcome
the -X- _ I-Outcome
rate -X- _ I-Outcome
of -X- _ I-Outcome
bleeding -X- _ I-Outcome
, -X- _ I-Outcome
death -X- _ I-Outcome
and -X- _ I-Outcome
PE -X- _ I-Outcome
recurrence -X- _ I-Outcome
were -X- _ I-Outcome
compared -X- _ I-Outcome
separately -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
hemodynamic -X- _ I-Outcome
instability -X- _ I-Outcome
and -X- _ I-Outcome
the -X- _ I-Outcome
massive -X- _ I-Outcome
anatomic -X- _ I-Outcome
obstruction -X- _ I-Outcome
subgroups -X- _ I-Outcome
, -X- _ I-Outcome
no -X- _ I-Outcome
significant -X- _ I-Outcome
difference -X- _ I-Outcome
was -X- _ I-Outcome
found. -X- _ I-Outcome
CONCLUSIONS -X- _ O
: -X- _ O
The -X- _ B-Outcome
UK-2 -X- _ I-Outcome
h -X- _ I-Outcome
regimen -X- _ I-Outcome
exhibits -X- _ I-Outcome
similar -X- _ I-Outcome
efficacy -X- _ I-Outcome
and -X- _ I-Outcome
safety -X- _ I-Outcome
as -X- _ I-Outcome
the -X- _ I-Outcome
UK-12 -X- _ I-Outcome
h -X- _ I-Outcome
regimen -X- _ I-Outcome
for -X- _ I-Outcome
acute -X- _ I-Outcome
PE. -X- _ I-Outcome
TRIAL -X- _ O
REGISTRATION -X- _ O
: -X- _ O
Clinical -X- _ O
trial -X- _ O
registered -X- _ O
with -X- _ O
http -X- _ O
: -X- _ O
/ -X- _ O
/ -X- _ O
clinicaltrials.gov -X- _ O
/ -X- _ O
ct2 -X- _ O
/ -X- _ O
show -X- _ O
/ -X- _ O
NCT00799968 -X- _ O
( -X- _ O
Identifier -X- _ O
: -X- _ O
NCT -X- _ O
00799968 -X- _ O
) -X- _ O

